Exploring how payments to doctors from drug companies affect cancer care quality and costs
Understanding the Importance of Industry Relationships for Cancer Care Quality, Outcomes, and Costs
This study looks at how payments from drug companies to cancer doctors might change the way they treat patients and the quality of care you receive, with the hope of improving cancer treatment for everyone.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10889015 on NIH RePORTER |
What this research studies
This research investigates the impact of financial relationships between pharmaceutical companies and physicians on the quality of cancer care and patient outcomes. It focuses on how personal payments to oncologists may influence their treatment decisions, potentially leading to variations in care quality and costs for patients. By analyzing data from Medicare claims and industry payment records, the study aims to uncover the relationship between these payments and the effectiveness of cancer treatments. The ultimate goal is to enhance understanding of how these financial ties affect patient care in the US healthcare system.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients receiving treatment from oncologists who may have financial ties to pharmaceutical companies.
Not a fit: Patients who are not currently undergoing cancer treatment or those receiving care from oncologists without industry relationships may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer care quality and better patient outcomes by informing policies that regulate physician-industry relationships.
How similar studies have performed: While the influence of industry payments on physician behavior has been noted, this specific investigation into its direct effects on cancer care quality and patient outcomes is relatively novel.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Mitchell, Aaron P — Sloan-Kettering Inst Can Research
- Study coordinator: Mitchell, Aaron P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.